Genomic Research in Sarcoidosis

Exclusion Criteria

• •1. History of comorbid condition severe enough to significantly increase risks based on investigator discretion.
• •2. Currently an active smoker.
• •3. Undergoing bronchoscopy (clinical or research) with any one of the following:
• •1. severe pulmonary impairment (\<50% predicted FVC, \<1 L FEV1; DLco \<40% predicted, resting hypoxemia \<92% with or without supplemental oxygen)
• •2. other co-morbid disease that would preclude bronchoscopy.
• •3. hypersensitivity to or intolerance of any of the drugs required for sedation during conscious sedation bronchoscopy.
• •4. Known systemic autoimmune disease such as rheumatoid arthritis, lupus, scleroderma, Sjögrens, etc.
• •5. Found to have an alternative interstitial lung disease during evaluation and/or screening.
• •6. Diagnosis of unstable cardiovascular disease including myocardial infarction in the past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia
• •7. Use of anticoagulation (patients on warfarin or clopidogrel will be excluded, patients on aspirin alone can be studied even with concurrent use)
• •8. Dementia or other cognitive dysfunction which in the opinion of the investigator would prevent the participant from consenting to the study or completing study procedures
• •9. Non-Sarcoidosis pulmonary disease (e.g., rheumatoid arthritis, lupus, scleroderma) that, in the opinion of the investigator, limits the interpretability of the analysis of sarcoidosis pulmonary disease
• •10. Primary biliary cirrhosis or autoimmune hepatitis
• •11. Crohn's disease
• •12. Chronic beryllium disease
• •13. Have an active bacterial or viral infection at time of screening.
• •14. Have an active or ongoing serious infection, including HIV, HBV and HCV
• •15. Active tuberculosis or are taking any medication for tuberculosis
• •16. Have a history of demyelinating diseases, lymphoproliferative diseases, or other malignancies other than presumed cured non-metastatic skin cancer
• •17. Have evidence of a likely malignancy on chest x-ray
• •18. Are currently pregnant at time of screening
• •19. Currently institutionalized (e.g., prisons, long-term care facilities)
• •20. Hypersensitivity to or intolerance of albuterol sulfate or propellants or excipients of the inhalers
• •21. History of Lung volume reduction surgery, lung resection or bronchoscopic lung volume reduction in any form.
• •22. History of lung or other organ transplant
• •23. Unable to comprehend consent document and/or questionnaires
• •Conditional Exclusions:
• •1. Participants who present with an upper respiratory infection or pulmonary exacerbation, either solely participant-identified or that has been clinically treated, in the last four weeks can be rescreened for the study once the four-week window has closed.
• •2. Participants who present with current use of acute antibiotics or have acute antibiotics within the past four weeks can be rescreened for the study ≥28 days after discontinuing acute antibiotics.
• •3. Female participants who present \<3 months after giving birth will be asked to reschedule their visit until three months have passed since the birth.
• •4. Former smoker who quit \< 3months prior to enrollment